Biotech Sophiris Bio sets terms for $65 million IPO

By
A A A

Sophiris Bio, a biotech focused on developing products for the treatment of urological diseases, announced terms for its IPO on Friday. The La Jolla, CA-based company plans to raise $65 million by offering 5.0 million shares at $13 per share. At a $13 offer price, Sophiris Bio would command a market value of $104 million. Sophiris Bio, which was founded in 2002, plans to list on the NASDAQ under the symbol SPHS. Sophiris Bio initially filed confidentially on December 7, 2012. Citi and Leerink Swann are the joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: SPHS

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com